Cannabis, Linked Emotions, and Adolescent Risk Study
Launched by MASSACHUSETTS GENERAL HOSPITAL · Aug 26, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Cannabis, Linked Emotions, and Adolescent Risk Study is looking to understand how using cannabis (marijuana) affects feelings of depression and thoughts of self-harm in teenagers aged 12 to 18. Researchers want to explore how cannabis use and withdrawal might change mood and the risk of suicide over time. By finding out more about these relationships, the study aims to help create better support and treatment options for young people struggling with these issues.
To participate, teens must be between 12 and 18 years old, use cannabis almost every day, and currently have symptoms of depression or thoughts about self-harm. Participants will need a smartphone and must have a parent or guardian's permission if they are under 18. Throughout the study, they will receive prompts to share their experiences and feelings, which will help researchers gather important information. This study is currently recruiting participants, and it’s a chance to contribute to understanding and improving mental health support for adolescents.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Ages 12-18;
- • Current daily or near daily cannabis use (i.e., use ≥ 4 days per week on average; Timeline Followback);
- • Score ≥ 5 on PHQ-9 or current depressive episode (Mini International Neuropsychiatric Interview Kid 7.0.2);
- • Access to an internet-capable smartphone (iOS or Android);
- • Provision of at least 1 collateral contact for risk monitoring;
- • Provision of informed assent (or consent if 18 years or older) and parent/guardian consent if \<age 18;
- • Greater than 60% response rate to EMA prompts during the first EMA phase;
- • No immediate plan to discontinue cannabis use in the next 3 months;
- • Positive toxicology result for cannabis on baseline urinalysis.
- Exclusion Criteria:
- • Any factor that impairs ability to comprehend and effectively participate, including acute intoxication at time of consent;
- • Cannabis use \>4 times/day on average (to maximize likelihood of capturing mood and SI during non-use times);
- • Inability to speak/write English fluently;
- • Gross cognitive impairment, for example due to florid psychosis, intellectual disability, developmental delay, or neurodegenerative disease;
- • Current epilepsy diagnosis;
- • Individuals who are under the legal protection of the government or state (wards of the state);
- • Response of "No" to the knowledge check question regarding EMA suicidality response time;
- • Inability to wear Fitbit device.
About Massachusetts General Hospital
Massachusetts General Hospital (MGH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing medical research and patient care. As a prominent teaching hospital affiliated with Harvard Medical School, MGH plays a pivotal role in clinical trials across a wide range of disciplines, including cardiology, oncology, neurology, and more. The institution is dedicated to fostering innovative research that translates into effective therapies and improved health outcomes. MGH's Clinical Trials Office provides comprehensive support to facilitate the design, implementation, and management of clinical studies, ensuring adherence to the highest ethical standards and regulatory compliance. With a focus on collaboration and patient-centered care, MGH strives to enhance medical knowledge and contribute to the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Patients applied
Trial Officials
Randi M Schuster, PhD
Principal Investigator
Massachusetts General Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported